MGI(SH:688114) Zheng Quan Ri Bao·2026-02-27 23:12Core Viewpoint - The company reported preliminary financial data for the year 2025, indicating a decline in revenue and net profit, while also highlighting cost reduction measures and foreign exchange gains as contributing factors to the financial performance [1][4]. Financial Data and Indicators - The company achieved operating revenue of 2,779.61 million yuan, a year-on-year decrease of 7.73% [4]. - The net profit attributable to the parent company was -236.93 million yuan, with a year-on-year reduction in losses of 60.57% [4]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was -377.84 million yuan, with a year-on-year reduction in losses of 42.11% [4]. - Total assets at the end of the reporting period were 10,239.61 million yuan, a decrease of 0.73% year-on-year [4]. - Equity attributable to the parent company was 7,632.48 million yuan, a decrease of 3.27% year-on-year [4]. Operating Performance and Financial Condition - The decline in operating revenue and gross profit contribution was attributed to intensified market competition and a shift in product sales structure towards lower throughput gene sequencing products [5]. - Total sales, management, and R&D expenses decreased by approximately 19% year-on-year due to the implementation of quality improvement and efficiency enhancement measures [5][8]. - Fluctuations in foreign currency exchange rates led to an increase in foreign exchange gains [6]. - The company reversed tax provisions related to uncertainties from previous years, resulting in a decrease in income tax expenses [6]. Changes in Key Financial Metrics - Operating profit, total profit, and net profit attributable to the parent company after deducting non-recurring gains and losses saw a reduction in losses of 47.55%, 46.41%, and 42.11% respectively compared to the same period last year [7][8]. - The decrease in gross profit contribution was approximately 200 million yuan due to market competition and changes in product sales structure [8].